Catalent

duchenne muscular dystrophy
Biotech

FDA skips AdComm for Sarepta's DMD therapy, sets decision date

The FDA won’t be holding an advisory panel meeting for Sarepta’s SRP-9001, which could become the first gene therapy for Duchenne muscular dystrophy.
Gabrielle Masson Feb 28, 2023 8:00pm
3 three

Exelixis goes 3 in 3 with $30M for 3 Catalent programs

Nov 3, 2022 1:20pm
image of a few paragliders

Catalent shakes up leadership, taps new CEO—Chutes & Ladders

Jul 8, 2022 9:30am